Results 121 to 130 of about 274,676 (405)

MYC Binding Near Transcriptional End Sites Regulates Basal Gene Expression, Read‐Through Transcription, and Intragenic Contacts

open access: yesAdvanced Science, EarlyView.
MYC is a transcription factor (TF) that binds DNA near transcriptional start sites (TSSs) and within enhancer elements. Here, unappreciated sites of MYC binding in the vicinity of transcriptional end sites (TESs) of many genes in multiple cell types in association with numerous other TFs are described previously.
Huabo Wang   +5 more
wiley   +1 more source

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.

open access: yesBlood, 2018
We previously reported durable responses and manageable safety of ibrutinib from a 3-year follow-up of treatment-naïve (TN) older patients (≥65 years of age) and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia/small lymphocytic ...
S. O'brien   +15 more
semanticscholar   +1 more source

Neutrophils in chronic lymphocytic leukemia are permanently activated and have functional defects [PDF]

open access: yes, 2017
A growing body of studies highlights involvement of neutrophils in cancer development and progression. Our aim was to assess the phenotypic and functional properties of circulating neutrophils from patients with chronic lymphocytic leukemia (CLL).
Gabčová, Gabriela   +10 more
core   +1 more source

Cryo‐Inactivated Cancer Cells Derived Magnetic Micromotors for Tumor Immunotherapy

open access: yesAdvanced Science, EarlyView.
Cryo‐inactivated cancer cell‐based magnetic micromotors are developed for synergistic tumor immunotherapy via magnetic targeting. These micromotors can induce ferroptosis and immunogenic cell death, deliver tumor antigens, and activate the Mn2+‐dependent cGAS‐STING pathway. The system effectively suppresses tumor progression, recurrence, and metastasis,
Qingfei Zhang   +3 more
wiley   +1 more source

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.

open access: yesNew England Journal of Medicine, 2011
BACKGROUND The somatic genetic basis of chronic lymphocytic leukemia, a common and clinically heterogeneous leukemia occurring in adults, remains poorly understood.
Lili Wang   +28 more
semanticscholar   +1 more source

Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC [PDF]

open access: yes, 2012
PMCID: PMC3526610This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
A Trojan   +56 more
core   +2 more sources

Alemtuzumab in Chronic Lymphocytic Leukemia

open access: yesCurrent Oncology, 2007
Questions: (1) With respect to outcomes such as survival, response rate, response duration, time to progression, and quality of life, is alemtuzumab a beneficial treatment option for patients with B-cell chronic lymphocytic leukemia (CLL)? (2) What toxicities are associated with the use of alemtuzumab? (3) Which patients are more likely—or less likely—
Fraser, G.   +3 more
openaire   +3 more sources

Extended lymphadenectomy for high-risk prostate cancer in patients with chronic lymphocytic leukemia may not be necessary: a report of two cases

open access: yesBMC Cancer, 2019
Background Chronic lymphocytic leukemia is a malignancy with good prognosis. However, the incidence of secondary tumors increases every year after the diagnosis of chronic lymphotcytic leukemia. One of the induced secondary tumors is prostate cancer. For
Yinjie Zhu   +6 more
doaj   +1 more source

CXCL13 Expression Promotes CAR T Cell Antitumor Activity and Potentiates Response to PD‐1 Blockade

open access: yesAdvanced Science, EarlyView.
This study demonstrates that engineering CAR T cells to express CXCL13 enhances their antitumor efficacy and significantly improves responsiveness to PD‐1 immune checkpoint blockade. CXCL13 promotes T cell persistence, and resistance to early exhaustion via the AKT‐mTOR pathway.
Yang Zhou   +15 more
wiley   +1 more source

Generalized Integrated Functional Test for Regional Methylation Rates [PDF]

open access: yesarXiv, 2014
Motivation: Methods are needed to test pre-defined genomic regions such as promoters for differential methylation in genome-wide association studies, where the number of samples is limited and the data have large amounts of measurement error. Results: We developed a new statistical test, the generalized integrated functional test (GIFT), which tests ...
arxiv  

Home - About - Disclaimer - Privacy